What Educators Should Know About Medication Use for Students With Emotional and Behavioral Disorders

Abstract

Psychotropic medications are increasingly being prescribed to school-age youth to address a variety of emotional and behavioral problems. In this article, we first provide an overview of these medications, their potential effects and side effects, and variables impacting their use. Prevalence of polypharmacy and rates of current and lifetime psychotropic medication use among children and adolescents are discussed. We then offer best practice recommendations for fostering positive, proactive, and productive relationships with caregivers and community-based agencies to improve multicomponent interventions that include medications.

Keywords

psychotropic medication emotional/behavioral disorders intervention

Get full access to this article

View all access options for this article.

References

American Academy of Child and Adolescent Psychiatry. (2015). Recommendations about the use of psychotropic medications for children and adolescents involved in child-serving systems [Executive summary]. https://www.aacap.org/App_Themes/AACAP/docs/clinical_practice_center/systems_of_care/AACAP_Psychotropic_Medication_Recommendations_2015_FINAL.pdf

Asselmann

Wittchen

H.-U.

Lieb

Beesdo-Baum

(2018). Sociodemographic, clinical, and functional long-term outcomes in adolescents and young adults with mental disorders. Acta Psychiatrica Scandinavica, 137(1), 6–17. https://doi.org/10.1111/acps.127922

Bilgili-Karabacak

Hand

S. L.

Settanni

Ivory

K. P.

Chen

Kern

Evans

S. W.

Aregood

E. K.

Dever

B. V.

(2023). Variables associated with medication use among high school students with emotional and behavioral problems. School Mental Health, 15, 873–885. https://doi.org/10.1007/s12310-023-09592-z

Briars

Todd

(2016). A review of pharmacological management of attention-deficit/hyperactivity disorder. The Journal of Pediatric Pharmacology and Therapeutics, 21(3), 192–206. https://doi.org/10.5863/1551-6776-21.3.192

Centers for Disease Control and Prevention. (2019). The youth risk behavior survey data summary & trends report: 2009–2019. https://www.cdc.gov/healthyyouth/data/yrbs/pdf/YRBSDataSummaryTrendsReport2019-508.pdf\

Centers for Disease Control and Prevention. (2024, June 21). Data and statistics on children’s mental health. https://www.cdc.gov/childrensmentalhealth/data.html

Ciesielski

H. A.

Loren

R. E.

Tamm

(2020). Behavioral parent training for ADHD reduces situational severity of child noncompliance and related parental stress. Journal of Attention Disorders, 24(5), 758–767. https://doi.org/10.1177/1087054719843181

Coles

E. K.

Pelham

W. E.

Fabiano

G. A.

Gnagy

E. M.

Burrows-MacLean

Wymbs

B. T.

Chacko

Walker

K. S.

Wymbs

Mazzant

J. R.

Garefino

Hoffman

M. T.

Massetti

G. M.

Page

T. F.

Waschbusch

D. A.

Waxmonsky

J. G.

Pelham

W. E.

(2020). Randomized trial of first-line behavioral intervention to reduce need for medication in children with ADHD. Journal of Clinical Child & Adolescent Psychology, 49(5), 673–687. https://doi.org/10.1080/15374416.2019.1630835

Danielson

M. L.

Bitsko

R. H.

Ghandour

R. M.

Holbrook

J. R.

Kogan

M. D.

Blumberg

S. J.

(2018). Prevalence of parent-reported ADHD diagnosis and associated treatment among U.S. children and adolescents, 2016. Journal of Clinical Child & Adolescent Psychology, 47(2), 199–212. https://doi.org/10.1080/15374416.2017.1417860

10.

Dopheide

J. A.

Pliszka

S. R.

(2009). Attention-deficit-hyperactivity disorder: An update. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 29(6), 656–679. https://doi.org/10.1592/phco.29.6.656

11.

Ellington

Lyons

(2023). Neuroscience-based nomenclature for psychotropic medication. Journal of Psychosocial Nursing & Mental Health Services, 61(7), 9–13. https://doi.org/10.3928/02793695-20230607-02

12.

Evans

S. W.

Pelham

W. E.

Smith

B. H.

Bukstein

Gnagy

E. M.

Greiner

A. R.

Altenderfer

Baron-Myak

(2001). Dose–response effects of methylphenidate on ecologically valid measures of academic performance and classroom behavior in adolescents with ADHD. Experimental and Clinical Psychopharmacology, 9(2), 163–175. https://doi.org/10.1037/1064-1297.9.2.163

13.

Forness

S. R.

Freeman

S. F.

Paparella

Kauffman

J. M.

Walker

H. M.

(2012). Special education implications of point and cumulative prevalence for children with emotional or behavioral disorders. Journal of Emotional and Behavioral Disorders, 20(1), 4–18. https://doi.org/10.1177/1063426611401624

14.

Fusar-Poli

McGorry

P. D.

Kane

J. M.

(2017). Improving outcomes of first-episode psychosis: An overview. World Psychiatry, 16(3), 251–265. https://doi.org/10.1002/wps.20446

15.

George

M. W.

Zaheer

Kern

Evans

S. W.

(2018). Mental health service use among adolescents experiencing emotional/behavioral problems and school impairment. Journal of Emotional and Behavioral Disorders, 26(2), 119–128. https://doi.org/10.1177/1063426617710240

16.

Girand

H. L.

Litkowiec

Sohn

(2020). Attention-deficit/hyperactivity disorder and psychotropic polypharmacy prescribing trends. Pediatrics, 146(1), Article e20192832. https://doi.org/10.1542/peds.2019-2832

17.

Goldberg

J. F.

Ernst

C. L.

(2019). Managing the side effects of psychotropic medications (2nd ed.). American Psychiatric Association.

18.

Grover

Avasthi

(2019). Clinical practice guidelines for the management of schizophrenia in children and adolescents. Indian Journal of Psychiatry, 61(8), 277–293. https://doi.org/10.4103/psychiatry.indianjpsychiatry_556_18

19.

Hales

C. M.

Kit

B. K.

Ogden

C. L.

(2018). Trends in prescription medication use among children and adolescents-United States, 1999-2014. JAMA, 319(19), 2009–2020. https://doi.org/10.1001/jama.2018.5690

20.

Kern

Weist

M. D.

Mathur

S. R.

Barber

B. R.

(2022). Empowering school staff to implement effective school mental health services. Behavioral Disorders, 47(3), 207–219. https://doi.org/10.1177/01987429211030860

21.

Lipscomb

Haimson

Liu

A. Y.

Burghardt

Johnson

D. R.

Thurlow

(2017). Preparing for life after high school: The characteristics and experiences of youth in special education—Findings from the National Longitudinal Transition Study 2012: Comparisons across disability groups. Full report (Vol. 2, NCEE 2017-4018). Department of Education, Institute of Education Sciences, National Center for Education Evaluation and Regional Assistance. https://ies.ed.gov/ncee/pubs/20174016/

22.

Lloyd

B. P.

Torelli

J. N.

Symons

F. J.

(2016). Issues in integrating psychotropic and intensive behavioral interventions for students with emotional and behavioral challenges in schools. Journal of Emotional and Behavioral Disorders, 24(3), 148–158. https://doi.org/10.1177/10634266166363

23.

Margherio

Evans

S. W.

Owens

J. S.

(2019). Universal screening in middle and high schools: Who falls through the cracks. School Psychology, 34, 591–602. https://doi.org/10.1037/spq0000337

24.

Mattison

R. E.

Rundberg-Rivera

Michel

(2014). Psychotropic medication characteristics for special education students with emotional and/or behavioral disorders. Journal of Child and Adolescent Psychopharmacology, 24(6), 347–353. https://doi.org/10.1089/cap.2013.0073

25.

McClain

M. B.

Shahidullah

J. D.

Harris

McIntyre

L. L.

Azad

(2022). Reconceptualizing educational contexts: The imperative for interprofessional and interagency collaboration in school psychology. School Psychology Review, 51(6), 742–754. https://doi.org/10.1080/2372966x.2021.1949247

26.

Mingebach

Kamp-Becker

Christiansen

Weber

(2018). Meta-meta-analysis on the effectiveness of parent-based interventions for the treatment of child externalizing behavior problems. PLOS ONE, 13(9), Article e0202855. https://doi.org/10.1371/journal.pone.0202855

27.

Mitchell

B. S.

Kern

Conroy

(2019). Supporting students with emotional or behavioral disorders: State of the field. Behavioral Disorders, 44(2), 70–84. https://doi.org/10.1177/0198742918816518

28.

Mojtabai

Olfson

(2020). National trends in mental health care for U.S. adolescents. Journal of the American Medical Association Psychiatry, 77(7), 703–714. https://doi.org/10.1001/jamapsychiatry.2020.0279

29.

Molina

B. S. G.

Hinshaw

S. P.

Swanson

J. M.

Arnold

L. E.

Vitiello

Jensen

P. S.

Epstein

J. N.

Hoza

Hechtman

Abikoff

H. B.

Elliott

G. R.

Greenhill

L. L.

Newcorn

J. H.

Wells

K. C.

Wigal

Gibbons

R. D.

Hur

Houck

P. R

., & The MTA Cooperative Group. (2009). The MTA at 8 years: Prospective follow-up of children treated for combined-type ADHD in a multisite study. Journal of the American Academy of Child & Adolescent Psychiatry, 48(5), 484–500. https://doi.org/10.1097/CHI.0b013e31819c23d0

30.

Ong

M. S.

Lakoma

Gees Bhosrekar

Hickok

McLean

Murphy

Poland

R. E.

Purtell

Ross-Degnan

(2021). Risk factors for suicide attempt in children, adolescents, and young adults hospitalized for mental health disorders. Child and Adolescent Mental Health, 26(2), 134–142. https://doi.org/10.1111/camh.12400

31.

Pelham

W. E.

III. Altszuler

A. R.

Merrill

B. M.

Raiker

J. S.

Macphee

F. L.

Ramos

Gnagy

E. M.

Greiner

A. R.

Coles

E. K.

Connor

C. M.

Lonigan

C. J.

Burger

Morrow

A. S.

Zhao

Swanson

J. M.

Waxmonsky

J. G.

Pelham

W. E.

Jr. (2022). The effect of stimulant medication on the learning of academic curricula in children with ADHD: A randomized crossover study. Journal of Consulting and Clinical Psychology, 90(5), 367–380. https://doi.org/10.1037/ccp0000725

32.

Ramey

D. M.

Freelin

B. N.

(2023). Exploring the relationships between school suspension, ADHD diagnoses, and delinquency across different school punitive and special education climates. Children and Youth Services Review, 148, Article 106849. https://doi.org/10.1016/j.childyouth.2023.106849

33.

Rapee

R. M.

Creswell

Kendall

P. C.

Pine

D. S.

Waters

A. M.

(2023). Anxiety disorders in children and adolescents: A summary and overview of the literature. Behaviour Research and Therapy, 168, Article 104376. https://doi.org/10.1016/j.brat.2023.104376

34.

Reuben

Elgaddal

(2024). Attention-deficit/hyperactivity disorder in children ages 5–17 years: United States, 2020–2022. https://www.cdc.gov/nchs/products/databriefs/db499.htm

35.

Rodgers

C. R. R.

Flores

M. W.

Bassey

Augenblick

J. M.

Cook

B. L.

(2022). Racial/ethnic disparity trends in children’s mental health care access and expenditures from 2010–2017: Disparities remain despite sweeping policy reform. Journal of the American Academy of Child and Adolescent Psychiatry, 61(7), 915–925. https://doi.org/10.1016/j.jaac.2021.09.420

36.

Ryan

J. B.

Katsiyannis

Ellis

(2015). Increasing role of medication therapy for managing student behavior. Beyond Behavior, 24(3), 31–37. https://doi.org/10.1177/107429561502400305

37.

Shahidullah

J. D.

Roberts

Parkhurst

Ballard

Mautone

J. A.

Carlson

J. S.

(2023). State of the evidence for use of psychotropic medications in school-age youth. Children, 10(9), Article 1454. https://doi.org/10.3390/children10091454

38.

Sullivan

A. L.

Sadeh

(2015). Psychopharmacological treatment among adolescents with disabilities: Prevalence and predictors in a nationally representative sample. School Psychology Quarterly, 30(5), 443–455. https://doi.org/10.1037/spq0000105

39.

Williamson

Koro-Ljungberg

Bussing

(2009). Analysis of critical incidents and shifting perspectives: Transitions in illness careers among adolescents with ADHD. Qualitative Health Research, 19(3), 352–365. https://doi.org/10.1177/1049732308329683

40.

Zhang

Spence

O. M.

Reeves

dosReis

(2021). Characteristics of youths treated with psychotropic polypharmacy in the United States, 1999 to 2015. Journal of the American Medical Association Pediatrics, 175, 196–198. https://doi.org/10.1001/jamapediatrics.2020.4678

41.

Zito

J. M.

Zhu

Safer

D. J.

(2021). Psychotropic polypharmacy in the U.S. pediatric population: A methodologic critique and commentary. Frontiers in Psychiatry, 12, Article 644741. https://doi.org/10.3389/fpsyt.2021.644741